Russia’s Enteromix Cancer Vaccine: A Breakthrough in Oncology or a Work in Progress?
Russia’s Enteromix, a personalized mRNA-based cancer vaccine, has shown 100% efficacy in early trials, targeting colorectal cancer, glioblastoma, and melanoma. Developed by the National Medical Research Radiological Centre and Engelhardt Institute, it combines mRNA technology with oncolytic viruses to train the immune system to attack cancer cells with precision, offering a safer alternative to chemotherapy. Awaiting regulatory approval, Enteromix could reshape oncology and inspire MedTech startups, though global access and pricing remain uncertain.










